Theralase® Technologies Inc. plans to extend the expiry date of 4,800,000 share purchase warrants from June 30, 2025, to June 30, 2028. The warrants, issued in 2023, remain exercisable at $0.35 per share under the same terms. The extension is subject to TSX Venture Exchange approval. Theralase® develops light- and drug-activated therapies targeting cancer, bacteria, and viruses.

Theralase® Technologies Inc. closed a $571,000 private placement, issuing 2,855,000 units at $0.20 each. Funds will support its Phase II bladder cancer trial, Rutherrin® development, and corporate needs. Each unit includes a share and a five-year warrant at $0.30. Insider participation totaled 669,700 units. The offering awaits TSX Venture Exchange approval.

Theralase® successfully completed its 2025 Annual General Meeting, sharing strategic plans for 2025–2026 focused on clinical advancements and commercialization. A recording of the presentation is available for shareholders.

Theralase® Technologies Inc. reminds shareholders of its Annual General and Special Meeting (AGSM) on June 11, 2025, at 4:30 pm ET in Toronto. Following the meeting, a virtual corporate presentation and Q&A session will be held at 5:15 pm ET via Zoom to discuss strategic objectives for 2025-2026. An archived recording will be available the next business day.

Theralase® reported Q1 2025 results showing lower revenue and increased R&D expenses, ongoing Study II enrollment with promising bladder cancer interim data, continued HSV treatment development, and plans for Rutherrin® clinical trials starting early 2026 targeting multiple cancers.

Theralase® will present preclinical data comparing radiation-activated Rutherrin® versus radiation alone at ASTRO 2025, highlighting tumor targeting, immune activation, and survival benefits; clinical trials for various cancers begin early 2026.

Theralase®’s Rutherrin® is 100x more effective than radiation alone in preclinical cancer models, showing tumor targeting, immune activation, and improved survival; Phase I/II clinical trials start early 2026 targeting multiple cancers.

Theralase advances Ruvidar® trials for bladder and other cancers, targeting NDA submissions by 2026, launching multiple Phase I/II studies, seeking US listing, and pursuing international partnerships for commercialization and research collaboration.

Theralase® presented interim Phase II data showing Ruvidar™’s strong safety and efficacy in treating BCG-unresponsive bladder cancer, with durable complete responses, no serious drug-related adverse events, and potential for regulatory approval in 2026.

Theralase® announces Ruvidar™ inhibits Deubiquitinating Enzymes (DUBs), a key factor in cancer and drug resistance. This dual action—blocking DUBs and inducing oxidative stress—makes Ruvidar™ a promising cancer therapy candidate.